Affini-T is a leading clinical stage precision immunotherapy company targeting oncogenic driver mutations, beginning with KRAS, to develop potentially curative therapies for patients with solid tumors. We are advancing two distinct T Cell Receptor (TCR) based therapeutic modalities encompassing adoptive cellular therapies and bispecific T Cell Engagers, each designed to harness T cell immunity with unprecedented precision and potency against solid tumors. Our most advanced TCR T-cell therapies are built based on state-of-the-art engineering, synthetic biology, and gene editing proprietary platforms overcoming the challenges of addressing solid tumors. Our T Cell therapies have high specificity and the multi-faceted ability to strike and persist within the solid tumors. Building on the world-class innovation inherent in our leadership team, founders and differentiating technologies, we are powered to develop transformational medicines that last.
Company Details
- Employees
- 43
- Address
- 100 Forge Rd, Watertown,massachusetts 02472,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.affinittx.com/
- HQ
- Watertown, Massachusetts
Affini-T Therapeutics Questions
Affini-T Therapeutics's website is https://www.affinittx.com/
Affini-T Therapeutics's LinkedIn profile is https://www.linkedin.com/company/affini-t-therapeutics
Affini-T Therapeutics has
43 employees.
View email and phone details for 43
employees at Affini-T Therapeutics.
Affini-T Therapeutics's industry is
Biotechnology Research
Affini-T Therapeutics's top competitors are
Remix Therapeutics,
Kymera Therapeutics,
Abata Therapeutics,
Immatics,
Gentibio,
Tscan Therapeutics,
Arsenal Biosciences, Inc.,
Orna Therapeutics,
Vigil Neuroscience,
Beam Therapeutics.
Affini-T Therapeutics's categories are Biotechnology Research
